Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party

Conclusion: For AML patients with FLT3 mutation, post-transplant sorafenib whether given as prophylactic or preemptive therapy or as treatment for relapse, significantly improves OS and may be considered as standard of care in that setting.DisclosuresMohty: MaaT Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy; Jazz Pharmaceuticals: Honoraria, Research Funding, Speakers Bureau; Bristol Myers: Consultancy, Research Funding; Janssen: Honoraria, Research Funding, Speakers Bureau; Molmed: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Takeda: Honoraria, Speakers Bureau.

Source: Blood - November 21, 2018 Category: Hematology Authors: Bazarbachi, A., Labopin, M., Battipaglia, G., Djabali, A., Forcade, E., Arcese, W., Socie, G., Blaise, D., Passweg, J. R., Cornelissen, J. J., Chevallier, P., Maertens, J., Schaap, N., Hashaishi, K., Elcheikh, J., Malard, F., Esteve, J., Nagler, A., Mohty Tags: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence: Therapy of Post-Transplantation Relapse Source Type: research